keyword
MENU ▼
Read by QxMD icon Read
search

alopecia universalis

keyword
https://www.readbyqxmd.com/read/28140540/sequential-high-and-low-dose-systemic-corticosteroid-therapy-for-severe-childhood-alopecia-areata
#1
Karin Jahn-Bassler, Wolfgang Michael Bauer, Franz Karlhofer, Matthias G Vossen, Georg Stingl
BACKGROUND: Given the limited number of therapeutic options, severe childhood alopecia areata (AA) poses a clinical challenge. The best and most rapid response rates can be achieved with high-dose systemic corticosteroids, however, relapse following treatment discontinuation is inevitable. Due to systemic side effects, long-term high-dose corticosteroid regimens are not feasible. Following initial pulse therapy, continuation of corticosteroid therapy at a dose below the Cushing threshold might be able to suppress disease activity without causing severe side effects...
January 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28140533/kombinierte-hoch-niedrig-dosis-therapie-mit-systemischen-glukokor-tikoiden-bei-schweren-verlaufsformen-der-alopecia-areata-im-kindesalter
#2
Karin Jahn-Bassler, Wolfgang Michael Bauer, Franz Karlhofer, Matthias G Vossen, Georg Stingl
HINTERGRUND: Schwere Verlaufsformen der Alopecia areata (AA) im Kindesalter sind aufgrund limitierter Optionen therapeutisch herausfordernd. Systemische, hochdosierte Glukokortikoide weisen die schnellste Ansprechrate auf, nach dem Absetzen kommt es allerdings zu Rezidiven. Eine längerfristige Hochdosis-Anwendung ist aufgrund der zu erwartenden Nebenwirkungen nicht empfehlenswert. Eine dauerhafte Steroiderhaltungstherapie unterhalb der Cushing-Schwellen-Dosis nach Bolustherapie könnte die Krankheitsaktivität ohne Nebenwirkungen längerfristig unterdrücken...
January 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28101018/remarkable-improvement-of-nail-changes-in-alopecia-areata-universalis-with-10-months-of-treatment-with-tofacitinib-a-case-report
#3
Sineida Berbert Ferreira, Morton Scheinberg, Denise Steiner, Tatiana Steiner, Gustavo Longhi Bedin, Rachel Berbert Ferreira
Alopecia areata (AA) is a chronic, autoimmune disease. The main symptom is massive hair loss, localized or diffuse, in the scalp and the whole body. However, nails may also be involved, and brittleness, fragility and pitting can be signs of nail dystrophy in AA patients. Here, we report the case of a male patient with AA refractory to various treatments, including oral, topical and intralesional corticosteroids, immunosuppressants, cyclosporin and PUVA (oxoralen plus ultraviolet light), all interrupted due to side effects...
September 2016: Case Reports in Dermatology
https://www.readbyqxmd.com/read/28077132/foxn1-deficient-nude-severe-combined-immunodeficiency
#4
REVIEW
Ioanna A Rota, Fatima Dhalla
Nude severe combined immunodeficiency is a rare inherited disease caused by autosomal recessive loss-of-function mutations in FOXN1. This gene encodes a transcription factor essential for the development of the thymus, the primary lymphoid organ that supports T-cell development and selection. To date nine cases have been reported presenting with the clinical triad of absent thymus resulting in severe T-cell immunodeficiency, congenital alopecia universalis and nail dystrophy. Diagnosis relies on testing for FOXN1 mutations, which allows genetic counselling and guides therapeutic management...
January 11, 2017: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/28074525/efficacy-of-superficial-cryotherapy-on-the-eyebrows-of-patients-with-alopecia-universalis-also-treated-with-contact-immunotherapy-on-the-scalp-a-prospective-split-face-comparative-study
#5
Sung Jay Choe, Won-Soo Lee
BACKGROUND: Few treatment modalities are available for treating alopecia areata (AA) of the eyebrow. Due to the anatomical proximity of the eyebrows to the eyes, safety issues and side effects should always be taken into consideration when choosing the treatment modality. This study was designed to examine the efficacy of superficial cryotherapy on patients with AA of the eyebrow. METHODS: Superficial cryotherapy was performed every other week on the right eyebrow (SC-treated) in a total of 20 patients who had been previously treated with diphenylcyclopropenone (DPCP) immunotherapy on the scalp...
February 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/27943234/immune-related-alopecia-areata-and-universalis-type-in-cancer-patients-receiving-immune-checkpoint-inhibitors
#6
A Zarbo, V R Belum, V Sibaud, S Oudard, M A Postow, J J Hsieh, R J Motzer, K J Busam, M E Lacouture
CTLA-4, PD-1, and PD-L1 monoclonal antibodies, commonly known as immune checkpoint inhibitors, are used for the treatment of various malignancies. The mechanism of action involves the inhibition of negative regulators of immune activation, which results in many patients developing immune-related adverse events (irAEs) including endocrinopathies, pneumonitis, colitis, hepatitis and dermatologic events. Dermatologic irAEs include maculopapular rash, pruritus, vitiligo, blistering disorders, mucocutaneous lichenoid eruptions, rosacea, and exacerbation of psoriasis...
December 11, 2016: British Journal of Dermatology
https://www.readbyqxmd.com/read/27843927/alopecia-areata-as-a-manifestation-of-systemic-lymphoma-report-of-two-cases
#7
Yuval Ramot, Alexander Gural, Abraham Zlotogorski
Alopecia areata is a common autoimmune disorder leading to hair loss. It usually affects individuals under the age of 40, and first appearance in older subjects is considered uncommon. Here, we report 2 cases of rapidly progressing alopecia areata, which appeared for the first time in adults. Patient 1 had alopecia universalis, which preceded the identification of hepatosplenic T-cell lymphoma, a rare form of lymphoma. Patient 2 suffered from the ophiasis type of alopecia areata, presenting for the first time following chemotherapy for non-Hodgkin B-cell lymphoma...
September 2016: Skin Appendage Disorders
https://www.readbyqxmd.com/read/27816293/tofacitinib-for-the-treatment-of-severe-alopecia-areata-and-variants-a-study-of-90-patients
#8
Lucy Y Liu, Brittany G Craiglow, Feng Dai, Brett A King
BACKGROUND: Alopecia areata (AA) is a common autoimmune disorder. There are no reliably effective therapies for AA. OBJECTIVE: We sought to evaluate the safety and efficacy of the Janus kinase 1/3 inhibitor, tofacitinib, in a series of patients over an extended period of time. METHODS: This is a retrospective study of patients age 18 years or older with AA with at least 40% scalp hair loss treated with tofacitinib. The primary end point was the percent change in Severity of Alopecia Tool (SALT) score during treatment...
January 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27741937/alopecia-universalis-as-a-side-effect-of-pegylated-interferon-%C3%AE-ribavirin-combination-therapy-for-hepatitis-c-a-rare-case-report
#9
Poonam Verma, Surabhi Dayal, V K Jain, Ashish Amrani
Pegylated interferon α and ribavirin therapy is associated with increased incidence of various systemic and cutaneous side effects. Among the side effects of this therapy, alopecia universalis is a rarely reported side effect which causes significant cosmetic concern to the patient. We report a rare case of alopecia universalis which developed eight weeks after discontinuation of this antiviral combination therapy. This gains importance because it is essential to sensitize the treating gastroenterologist and the dermatologist regarding this rare side effect...
October 14, 2016: Journal of Chemotherapy
https://www.readbyqxmd.com/read/27730032/serum-vitamin-d-in-patients-with-alopecia-areata
#10
Ola Ahmed Bakry, Shawky M El Farargy, Maathir K El Shafiee, Amira Soliman
BACKGROUND: Alopecia areata (AA) is a common, recurrent, autoimmune hair disorder. It has been found that vitamin D deficiency is associated with many autoimmune diseases. AIMS: The current study aimed to estimate serum levels of 25-hydroxy vitamin D in patients with AA. MATERIALS AND METHODS: This case-control study included 60 patients with AA and 60 age, gender, skin phototype, and body mass index-matched healthy subjects as a control group...
September 2016: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/27699252/safety-and-efficacy-of-the-jak-inhibitor-tofacitinib-citrate-in-patients-with-alopecia-areata
#11
Milène Kennedy Crispin, Justin M Ko, Brittany G Craiglow, Shufeng Li, Gautam Shankar, Jennifer R Urban, James C Chen, Jane E Cerise, Ali Jabbari, Mårten C G Winge, M Peter Marinkovich, Angela M Christiano, Anthony E Oro, Brett A King
BACKGROUND: Alopecia areata (AA) is an autoimmune disease characterized by hair loss mediated by CD8(+) T cells. There are no reliably effective therapies for AA. Based on recent developments in the understanding of the pathomechanism of AA, JAK inhibitors appear to be a therapeutic option; however, their efficacy for the treatment of AA has not been systematically examined. METHODS: This was a 2-center, open-label, single-arm trial using the pan-JAK inhibitor, tofacitinib citrate, for AA with >50% scalp hair loss, alopecia totalis (AT), and alopecia universalis (AU)...
September 22, 2016: JCI Insight
https://www.readbyqxmd.com/read/27677412/vitiligo-on-black-skin-epidemiological-and-clinical-aspects-in-dermatology-cotonou-benin
#12
Bérénice Dégboé, Félix Atadokpèdé, Bayaki Saka, Hugues Adégbidi, Christiane Koudoukpo, Hubert Yédomon, Florencia do Ango-Padonou
BACKGROUND: Vitiligo is unsightly on darkly pigmented skin and leads important stigmatization because of the mix-up with leprosy. PATIENTS AND METHODS: We analyzed retrospectively the epidemiological and clinical patterns of vitiligo on darkly pigmented skin between 1988 and 2008 in the Department of Dermatology in Cotonou (Benin). The diagnosis was made based on the clinical characteristics of vitiligo. RESULTS: Two hundred and forty-six patients were seen, representing 0...
January 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/27644142/alopecia-universalis-in-a-dog-with-testicular-neoplasia
#13
Catherine A Outerbridge, Stephen D White, Verena K Affolter
OBJECTIVE: To describe a case of testicular neoplasia and alopecia universalis in a dog, and successful treatment of the latter with ciclosporin. ANIMAL: Twelve-year-old intact male wirehaired fox terrier. METHODS: Castration, skin biopsy for histopathology, lymphocyte immunophenotyping and clonality analysis of the canine T-cell receptor gamma locus (TCRγ) rearrangement. RESULTS: The dog presented with symmetrical generalized alopecia...
December 2016: Veterinary Dermatology
https://www.readbyqxmd.com/read/27633379/hirschsprung-s-disease-associated-with-alopecia-universalis-congenita-a-case-report
#14
Sushma Malik, Mani Singhal, Shruti Sudhir Jadhav, Charusheela Sujit Korday, Chitra Shivanand Nayak
BACKGROUND: Hirschsprung's disease is one of the commonest causes of intestinal obstruction in neonates because of gut motility disorder. It is characterized as a complex genetic heterogenous disorder with variable inheritance. Hirschsprung's disease occurs as an isolated phenotype in majority (70 %) of cases. In other cases it may be associated with syndromes (such as Down's syndrome, Waardenburg syndrome, congenital central hypoventilation, or cartilage-hair hypoplasia) or with a spectrum of congenital anomalies involving neurological, cardiovascular, or urological systems or with sensorineural anomalies...
September 15, 2016: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/27608049/alopecia-areata-totalis-and-universalis-a-multicenter-review-of-132-patients-in-spain
#15
S Vañó-Galván, P Fernández-Crehuet, R Grimalt, M J Garcia-Hernandez, R Rodrigues-Barata, S Arias-Santiago, A Molina-Ruiz, E Garcia-Lora, J Dominguez-Cruz, A Brugues, J Ferrando, C Serrano-Falcón, S Serrano, J Paoli, F Camacho
BACKGROUND: Alopecia areata totalis (AAT) and universalis (AAU) pose a therapeutic challenge. OBJECTIVE: To describe the clinical and epidemiological features, therapeutic response and prognostic factors in a large series of patients diagnosed with AAT and AAU. METHODS: This retrospective multicenter study included patients diagnosed with AAT/AAU with a minimum follow-up of 12 months. Response was assessed based on the regrowth of scalp hair...
October 6, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27503140/beard-alopecia-areata-a-multicentre-review-of-55-patients
#16
D Saceda-Corralo, R Grimalt, P Fernández-Crehuet, A Clemente, C Bernárdez, M J García-Hernandez, S Arias-Santiago, A R Rodrigues-Barata, A Rodríguez-Pichardo, E García-Lora, P Jaén, F M Camacho, S Vañó-Galván
BACKGROUND: Alopecia areata on the beard area (BAA) is a common clinical manifestation, but there are no studies about its characteristics. OBJECTIVE: To describe the epidemiology, comorbidities, clinical presentation, evolution, diagnostic findings and therapeutic choices in a series of patients with BAA. METHODS: This retrospective multicentre review included patients diagnosed with BAA as the first and unique clinical manifestation with at least 12 months of follow-up...
January 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27349217/successful-treatment-of-refractory-alopecia-areata-universalis-and-psoriatic-arthritis-but-not-of-plaque-psoriasis-with-tofacitinib-in-a-young-woman
#17
Ulrich Mrowietz, Sascha Gerdes, Regine Gläser, Oltmann Schröder
is missing (Short communication).
February 8, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/27322477/molecular-signatures-define-alopecia-areata-subtypes-and-transcriptional-biomarkers
#18
Ali Jabbari, Jane E Cerise, James C Chen, Julian Mackay-Wiggan, Madeleine Duvic, Vera Price, Maria Hordinsky, David Norris, Raphael Clynes, Angela M Christiano
Alopecia areata (AA) is an autoimmune disease typified by nonscarring hair loss with a variable clinical course. In this study, we conducted whole genome gene expression analysis of 96 human scalp skin biopsy specimens from AA or normal control subjects. Based on gene expression profiling, samples formed distinct clusters based on the presence or absence of disease as well as disease phenotype (patchy disease compared with alopecia totalis or universalis). Differential gene expression analysis allowed us to robustly demonstrate graded immune activity in samples of increasing phenotypic severity and generate a quantitative gene expression scoring system that classified samples based on interferon and cytotoxic T lymphocyte immune signatures critical for disease pathogenesis...
May 2016: EBioMedicine
https://www.readbyqxmd.com/read/27306107/efficacy-of-tofacitinib-in-treatment-of-alopecia-universalis-in-two-patients
#19
A K Gupta, J L Carviel, W Abramovits
BACKGROUND: Autoimmune-triggered non-scarring hair loss is a feature of alopecia areata (AA). Initially patchy and often self-limited, severe hair loss forms include the complete loss of scalp hair or alopecia totalis (AT) and complete loss of all hair or alopecia universalis (AU). For AT and AU a reliable treatment has remained elusive. The targeted kinase inhibitor tofacitinib, in current use for treatment of other immune diseases, has been hypothesized as a viable option for AA, AT and AU therapy and a few case reports support this...
August 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27279512/severe-subtype-of-alopecia-areata-is-highly-associated-with-thyroid-autoimmunity
#20
Ghada A Bin Saif
OBJECTIVES: To assess the significance of thyroid autoimmune screening in alopecia areata (AA) patients in Saudi population, and to determine whether there is a difference in thyroid autoimmune susceptibility between mild and severe AA. METHODS: In a prospective case-control study, we included 50 alopecia totalis (AT) and alopecia universalis (AU) patients, 50 age- and gender-matched patients with localized AA, and 50 age- and gender- matched healthy subjects between March 2015 and August 2015...
June 2016: Saudi Medical Journal
keyword
keyword
93734
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"